A record of what Raja Venkatraman said publicly, with the source. Not advice.
“Bullish on Panacea Biotec, recommending to buy above ₹431 with a stop loss at ₹405 and targets between ₹475-490. The stock shows a strong recovery after retesting an important support zone around ₹290-300, with the recent session giving a strong breakout and a gradual resumption of upward momentum, indicating more room at the top and a strong bullish case.”
Raja Venkatraman’s track record (trackable calls only): 616 graded calls · 95% CI 35–43%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.
Entry: ₹431, as stated.
Target ₹475, stop ₹405, as stated.
No time frame is stated, so it is tracked until a close reaches ₹475 or ₹405: there is no fixed window.
The target ₹475 was reached on a close before the stop ₹405. Hit.
The grader’s working: R3 TRADE_SETUP: entered ₹439 on 2025-03-27 (stated entry ₹431, TRIGGER entry, filled); target ₹475 reached at close ₹498.05 on 2025-04-16. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.